trending Market Intelligence /marketintelligence/en/news-insights/trending/mrwwiybryc0hgrlnz7w7cq2 content esgSubNav
In This List

US FDA flags violations at Alembic's Indian plant

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


US FDA flags violations at Alembic's Indian plant

Alembic Pharmaceuticals Ltd. said the U.S. Food and Drug Administration observed three violations at its formulation facility in India.

The U.S. regulator issued a Form 483 following an audit at the company's plant, located in India's Gujarat state.

A form 483 is issued when investigators observe any conditions or practices that may have violated the Food Drug and Cosmetic Act and could later pose health hazards to consumers.

Vadodara, Gujarat-based Alembic said none of the observations were related to data integrity or repetitive in nature.

The company said it will submit a response to the U.S. FDA shortly.